Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Invest New Drugs. 2018 Apr 3;36(6):1016–1025. doi: 10.1007/s10637-018-0591-z

Table 1.

Baseline patient demographic and clinical characteristics

Characteristic Patients
(N = 77)
Median age, years (range) 62 (25 to 89)
Sex, n (%)
  Female 51 (66)
  Male 26 (34)
Ethnicity, n (%)
  White 66 (85)
  Black 6 (8)
  American Indian 1 (1)
  Asian 4 (6)
Median height, cm (range) 167.0 (152.0 to 197.0)
Median weight, kg (range) 68.2 (42.0 to 119.0)
ECOG PS, n (%)
  0 50 (65)
  1 27 (35)
Tumor type, n (%)
  Endometrium/uterus 12 (16)
  Prostate 10 (13)
  Ovary 9 (12)
  Colon/rectum 9 (12)
  Breast 6 (8)
  Neuroendocrine 4 (5)
  Head and neck 4 (5)
  Other 23 (29)
Prior treatment regimens, n (%)
  Chemotherapy 69 (90)
  Biologic therapy (monoclonal antibodies) 39 (51)
  Hormonal therapy 20 (26)
  Immunotherapy 4 (5)
No. of prior chemotherapy regimens, n (%)
  1 12 (16)
  2 15 (19)
  3 12 (16)
  4 9 (12)
  >4 21 (27)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.